fluorouracil has been researched along with Cholera Infantum in 131 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This phase I/II dose-finding study evaluated gefitinib in combination with a 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI-AIO) regimen in patients with metastatic colorectal cancer." | 9.12 | Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO). ( Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J, 2006) |
| "To evaluate the maximum tolerated dose and dose-limiting toxicity (DLT) of 10-hydroxy-camptothecin (10-HCPT) in HFL regimen for the treatment of advanced colorectal cancer (CRC)." | 9.12 | [10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer]. ( Cai, RG; Chen, SS; Chu, DT; Wu, F; Zhang, HG, 2007) |
| "We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of protracted venous infusion (PVI) 5-fluorouracil (5-FU) against the standard bolus monthly regimen of 5-FU/leucovorin (LV) given for 6 months as adjuvant treatment in colorectal cancer (CRC)." | 9.11 | A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, JR; Ross, PJ; Tait, D; Webb, A, 2005) |
| "Docetaxel and capecitabine, a tumor-activated oral fluoropyrimidine, show high single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies." | 9.10 | Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. ( Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S, 2002) |
| "Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)." | 9.09 | Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000) |
| "On the strength of recent evidence of the activity of the combination of cisplatin and 5-fluorouracil against squamous malignancies of the esophagus and head and neck, this regimen was evaluated in a phase II trial against metastatic or recurrent squamous carcinoma of the uterine cervix." | 9.06 | A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. ( Alberts, DS; Boutselis, JG; Green, S; Hannigan, EV; Surwit, EA; Wallace, DL; Weiss, GR, 1990) |
| ", Nutley, NJ) is an orally administered fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an integral component of chemotherapy (CT) regimens for metastatic colorectal cancer (mCRC)." | 8.86 | Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. ( Boehm, KA; Cartwright, T; McCollum, D, 2010) |
| "To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer." | 8.85 | Capecitabine-based combination therapy for breast cancer: implications for nurses. ( Frye, DK, 2009) |
| "To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy." | 7.83 | Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016) |
| "Lafutidine could offer the possibility of more effective prevention of CT-induced mucositis through the activation of GI mucus cells." | 7.74 | Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. ( Goso, Y; Ichikawa, T; Ikezawa, T; Ishihara, K; Iwai, T; Nakano, M; Saegusa, Y; Saigenji, K; Shikama, N, 2008) |
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 7.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "Escalating doses of cyclophosphamide were given every 3 weeks as adjuvant treatment for women operated for breast cancer to determine the maximum tolerated dose of cyclophosphamide that can be given with constant doses of methotrexate (40 mg/m2) and 5-FU (600 mg/m2; CMF) as an outpatient treatment without the routine use of granulocyte colony-stimulating growth factor (G-CSF)." | 7.70 | Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer. ( Hietanen, P; Joensuu, H; Teerenhovi, L, 1999) |
| "We report an update of our results of a trial of high-dose folinic acid (HDFA) and 5-fluorouracil (5-FU) in advanced breast cancer." | 7.67 | 5-Fluorouracil and high-dose folinic acid as salvage treatment of advanced breast cancer: an update. ( Gorni, F; Marini, G; Marpicati, P; Simoncini, E; Zambruni, A; Zaniboni, A, 1987) |
| "Forty-four patients with advanced colorectal cancer, who had progressed during or within 3 months after completion of chemotherapy with LV/5-FU 24-h infusion (LV/5-FU(24h)) (eight patients) or irinotecan combined with or after LV/5-FU(24h )(36 patients), were treated with L-OHP 85 mg/m(2), 2-h intravenous (i." | 6.70 | Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. ( Atanackovic, D; Corovic, A; Gruber, Y; Hegewisch-Becker, S; Hossfeld, DK; Nierhaus, A; Pichlmeier, U, 2002) |
| " Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases." | 5.36 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010) |
| " This study determined the maximum-tolerated dose (MTD), toxicity, and pharmacokinetics of irinotecan (CPT-11), capecitabine, and epirubicin in patients with metastatic adenocarcinoma of lung, breast, or gastrointestinal tract." | 5.13 | Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. ( Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS, 2008) |
| "To evaluate the maximum tolerated dose and dose-limiting toxicity (DLT) of 10-hydroxy-camptothecin (10-HCPT) in HFL regimen for the treatment of advanced colorectal cancer (CRC)." | 5.12 | [10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer]. ( Cai, RG; Chen, SS; Chu, DT; Wu, F; Zhang, HG, 2007) |
| " This phase I/II dose-finding study evaluated gefitinib in combination with a 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI-AIO) regimen in patients with metastatic colorectal cancer." | 5.12 | Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO). ( Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J, 2006) |
| "We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of protracted venous infusion (PVI) 5-fluorouracil (5-FU) against the standard bolus monthly regimen of 5-FU/leucovorin (LV) given for 6 months as adjuvant treatment in colorectal cancer (CRC)." | 5.11 | A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, JR; Ross, PJ; Tait, D; Webb, A, 2005) |
| "Docetaxel and capecitabine, a tumor-activated oral fluoropyrimidine, show high single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies." | 5.10 | Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. ( Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S, 2002) |
| "The aim of this study was to evaluate the toxicity and efficacy of combination chemotherapy with weekly 24-h continuous infusion of 5-fluorouracil (5-FU)/folinic acid, weekly paclitaxel and 3-weekly cisplatin in patients with unresectable, locally advanced or metastatic gastric adenocarcinoma." | 5.10 | Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. ( Baronius, W; Bokemeyer, C; Haag, C; Hartmann, JT; Hempel, V; Honecker, F; Kanz, L; Kollmannsberger, C; Quietzsch, D; Schroeder, M; Spott, C, 2002) |
| "Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)." | 5.09 | Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000) |
| "In an attempt to improve the primary treatment of malignant gliomas we used a concomitant 6-week course of chemoradiotherapy with 5 fluorouracil (5 FU) and hydroxyurea (HU) in 24 adults with anaplastic astrocytoma (AA) (7 cases) or glioblastomas (GLB) (17 cases)." | 5.07 | Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. ( Armand, JP; Cioloca, C; Constans, JP; Cvitkovic, FB; Haie-Meder, C; Maugis, N; Papadimitrakopoulou, V, 1993) |
| "On the strength of recent evidence of the activity of the combination of cisplatin and 5-fluorouracil against squamous malignancies of the esophagus and head and neck, this regimen was evaluated in a phase II trial against metastatic or recurrent squamous carcinoma of the uterine cervix." | 5.06 | A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. ( Alberts, DS; Boutselis, JG; Green, S; Hannigan, EV; Surwit, EA; Wallace, DL; Weiss, GR, 1990) |
| "Two hundred forty-one patients with unresectable gastric adenocarcinoma were entered, between December 1978 and March 1981, into a prospectively randomized comparison of three chemotherapy regimens to identify therapeutic activity and determine patient tolerability: (1) 5-fluorouracil plus Adriamycin (FA); (2) FA plus methyl-CCNU (FAMe); and (3) FA plus mitomycin C (FAMi)." | 5.05 | Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group. ( , 1984) |
| ", Nutley, NJ) is an orally administered fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an integral component of chemotherapy (CT) regimens for metastatic colorectal cancer (mCRC)." | 4.86 | Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. ( Boehm, KA; Cartwright, T; McCollum, D, 2010) |
| "To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer." | 4.85 | Capecitabine-based combination therapy for breast cancer: implications for nurses. ( Frye, DK, 2009) |
| "We reviewed published studies reporting phase II and III clinical trials of dose-dense regimens for breast cancer and NHL, TAC (docetaxel, adriamycin, cyclophosphamide) chemotherapy for breast cancer, and infusional 5-fluorouracil-based regimens for colorectal cancer." | 4.83 | Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. ( Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M, 2006) |
| "To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy." | 3.83 | Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016) |
| " We tested whether SGLT-1 engagement might protect the intestinal mucosa from doxorubicin (DXR)- and 5-fluorouracil (5-FU)-induced injury in animal models mimicking acute or chronic mucositis." | 3.80 | Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis. ( Balsari, A; Cardani, D; D'Orazio, G; Koepsell, H; La Ferla, B; Marcucci, F; Nicotra, F; Olivero, D; Rumio, C; Sardi, C; Sommariva, M; Tagliabue, E, 2014) |
| "From March 2009 through April 2012, 22 patients were treated with proton therapy and concomitant capecitabine (1000 mg PO twice daily) for resected (n = 5); marginally resectable (n = 5); and unresectable/inoperable (n = 12) biopsy-proven pancreatic and ampullary adenocarcinoma." | 3.79 | Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. ( Asbun, HJ; Awad, ZT; George, TJ; Ho, MW; Hoppe, BS; Huh, S; Mendenhall, NP; Morris, CG; Nichols, RC; Zaiden, RA, 2013) |
| " The current study was designed to prepare sustained release tablets of Capecitabine, which is approved by the Food and Drug Administration (FDA) for the treatment of advanced breast cancer, using hydroxypropyl methylcellulose (HPMC), carbomer934P, sodium alginate, and sodium bicarbonate." | 3.79 | Preparation and characterization of a gastric floating dosage form of capecitabine. ( Akbari Javar, H; Farjam, AS; Ibrahim Noordin, M; Kadivar, A; Kamalidehghan, B; Taghizadeh Davoudi, E, 2013) |
| "Diarrhea is a side effect of a 5-fluorouracil (5-FU) anti-cancer drug-induced intestinal mucosal disorder, which sometimes becomes more severe." | 3.77 | [Diamine oxidase as blood biomarker in rats and humans to GI tract toxicity of fluorouracil anti-cancer drugs]. ( Goto, T; Kouchi, Y; Matsubara, T; Moriyama, K; Nemoto, H; Sanada, Y; Sasaya, S; Yoshizawa, Y, 2011) |
| "Treatment-related safety data from three phase III clinical studies were analyzed by multivariate analysis: two comparing capecitabine with bolus FU/LV in metastatic colorectal cancer (MCRC) and one comparing capecitabine plus oxaliplatin (XELOX) with bolus FU/LV as adjuvant treatment for colon cancer." | 3.74 | Potential regional differences for the tolerability profiles of fluoropyrimidines. ( Allegra, C; Bertino, JR; Cassidy, J; Clarke, SJ; Cunningham, D; Douillard, JY; Gilberg, F; Gustavsson, BG; Haller, DG; Hoff, PM; Milano, G; O'Connell, M; Rothenberg, ML; Rustum, Y; Saltz, LB; Schmoll, HJ; Sirzén, F; Tabernero, J; Twelves, C; Van Cutsem, E, 2008) |
| "Lafutidine could offer the possibility of more effective prevention of CT-induced mucositis through the activation of GI mucus cells." | 3.74 | Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. ( Goso, Y; Ichikawa, T; Ikezawa, T; Ishihara, K; Iwai, T; Nakano, M; Saegusa, Y; Saigenji, K; Shikama, N, 2008) |
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 3.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "Escalating doses of cyclophosphamide were given every 3 weeks as adjuvant treatment for women operated for breast cancer to determine the maximum tolerated dose of cyclophosphamide that can be given with constant doses of methotrexate (40 mg/m2) and 5-FU (600 mg/m2; CMF) as an outpatient treatment without the routine use of granulocyte colony-stimulating growth factor (G-CSF)." | 3.70 | Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer. ( Hietanen, P; Joensuu, H; Teerenhovi, L, 1999) |
| "Fifty-one patients with metastatic adenocarcinoma received Folinic Acid (FA) combined with 5-Fluorouracil (5FU) in a Phase I-II clinical trial." | 3.67 | 5-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancy. ( Budd, GT; Bukowski, RM; Cunningham, J; Purvis, J; Weick, JK, 1984) |
| "We report an update of our results of a trial of high-dose folinic acid (HDFA) and 5-fluorouracil (5-FU) in advanced breast cancer." | 3.67 | 5-Fluorouracil and high-dose folinic acid as salvage treatment of advanced breast cancer: an update. ( Gorni, F; Marini, G; Marpicati, P; Simoncini, E; Zambruni, A; Zaniboni, A, 1987) |
| "Recommended dosage for future trials is capecitabine 625 mg/m bid, irinotecan 35 mg/m, and celecoxib 400 mg orally bid in combination with pelvic radiation." | 2.75 | A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. ( Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I, 2010) |
| "Of these, 50 patients had untreated gastric cancer, and 14 had received previous therapy with nonplatinum-based therapy." | 2.74 | Phase II study of capecitabine plus cisplatin in patients with gastric cancer. ( AL-Ashry, MS; Ebrahim, MA; Salah-Eldin, MA, 2009) |
| "To test the efficacy and safety of pharmacokinetic modulating chemotherapy combined with cisplatin (PMC-cisplatin) as induction chemotherapy (ICT) before definitive treatment in patients with respectable locally advanced head and neck squamous cell carcinoma (HNSCC)." | 2.73 | Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ( Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Wang, LW; Wang, YF; Yang, MH, 2008) |
| "The recommended phase II dose of PKC412 is 150 mg/day when combined with a continuous infusion of 200 mg/m2/day 5-FU." | 2.71 | A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. ( Campbell, A; Clark, JW; Deluca, P; Eder, JP; Garcia-Carbonero, R; LoRusso, P; Puchalski, TA; Rothermel, J; Ryan, DP; Supko, JG; Wozniak, A, 2004) |
| " 5-FU dosage was fixed at 1,600 mg/m2 while docetaxel was evaluated at weekly 1-hour infusion dosages of 30, 40 and 50 mg/m2 to determine the MTD." | 2.70 | A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. ( Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW, 2002) |
| "Forty-four patients with advanced colorectal cancer, who had progressed during or within 3 months after completion of chemotherapy with LV/5-FU 24-h infusion (LV/5-FU(24h)) (eight patients) or irinotecan combined with or after LV/5-FU(24h )(36 patients), were treated with L-OHP 85 mg/m(2), 2-h intravenous (i." | 2.70 | Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. ( Atanackovic, D; Corovic, A; Gruber, Y; Hegewisch-Becker, S; Hossfeld, DK; Nierhaus, A; Pichlmeier, U, 2002) |
| " This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic interaction between the two compounds." | 2.69 | A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. ( Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J, 2000) |
| "Four of ten patients with colorectal cancer responded to the treatment (four partial responses), of whom three had been treated previously." | 2.67 | A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. ( Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S, 1991) |
| "Fifty-seven Dukes C colorectal cancer patients were given 5-fluorouracil-interferon-alpha 2b adjuvant treatment from October 1986 to September 1990." | 2.67 | 5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer. ( Cremone, L; Espinosa, A; Faiella, F; Frasci, G; Leone, F; Monaco, M; Persico, G; Sapio, U, 1994) |
| "Gastrointestinal mucositis is a common and debilitating side-effect of anticancer therapy contributing to dose reductions, delays and cessation of treatment, greatly impacting clinical outcomes." | 2.66 | Impact of chemotherapy-induced enteric nervous system toxicity on gastrointestinal mucositis. ( Al Thaalibi, M; McQuade, RM; Nurgali, K, 2020) |
| "Patients with advanced colorectal cancer and no prior chemotherapy were randomized to six treatment regimens: A) fluorouracil (FU) alone; B) FU + hydroxyurea (HU); C) semustine (SE) + dacarbazine (DA); D) FU + HU alternating with SE + DA; E) SE + razoxane (RA); F) mitomycin (MI) + DA." | 2.65 | Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278). ( Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Mittelman, A, 1984) |
| "Severe gastrointestinal (GI) toxicity is a common adverse effect following 5-fluorouracil (5-FU)-based chemotherapy treatment." | 2.61 | Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy. ( Bowen, JM; Coller, JK; Gibson, RJ; Korver, SK, 2019) |
| "Inflammation is a key factor behind gastrointestinal (GI) toxicity of chemotherapy." | 2.50 | Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. ( Doherty, GA; Lee, CS; Ryan, EJ, 2014) |
| "A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen." | 2.46 | Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. ( Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R, 2010) |
| " We also explore different dosing and schedules of capecitabine administration." | 2.46 | Safety of capecitabine: a review. ( Marshall, JL; Mikhail, SE; Sun, JF, 2010) |
| " Severe (grade ≥III) toxicity in DPYD variant allele carriers receiving upfront FP dose reductions according to pharmacogenetic dosing guidelines and DPYD variant allele carriers not receiving FP dose reductions was compared with DPYD wild-type patients receiving standard dose of FPs in CRT." | 1.48 | Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. ( Cecchin, E; Dreussi, E; Fiocco, M; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Lunenburg, CATC; Meulendijks, D; Peters, FP; Schellens, JHM; Swen, JJ; Toffoli, G, 2018) |
| "Gastrointestinal toxicity is the most common adverse effect of chemotherapy." | 1.43 | Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats. ( Forsgård, RA; Frias, R; Holma, R; Korpela, R; Lindén, J; Österlund, P; Spillmann, T, 2016) |
| "To assess the frequency and severity of gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with four different schedules of FOLFOX." | 1.40 | Gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with different schedules of FOLFOX. ( Bano, N; Mateen, A; Najam, R; Qazi, F, 2014) |
| "Patients diagnosed with stage III colon cancer in 1991 to 2005 were identified from the Surveillance, Epidemiology, and End Results-Medicare database." | 1.38 | Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer. ( Chan, W; Delclos, GP; Du, XL; Hu, CY, 2012) |
| " Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases." | 1.36 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010) |
| "Progressive respiratory failure developed in a 68 year-old female who was treated with single-agent oxaliplatin for colorectal cancer." | 1.33 | Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. ( Colomer, R; Fabregat, MB; Merino, BQ; Puig, J; Soy, E; Yagüe, XH, 2005) |
| "A sample of 83 rectal cancer patients in Dukes' stages B2 or C who started a chemoradiotherapy treatment followed by surgery, have filled in the EORTC core questionnaire QLQC30 and the colorectal module QLQ-CR38, in three moments during the treatment and follow-up periods: at the beginning of the treatment, at the end of the chemoradiotherapy, and after surgery." | 1.33 | Quality of Life assessment through the EORTC questionnaires of locally advanced rectal cancer patients treated with preoperative chemo-radiotherapy. ( Arias de la Vega, F; Arraras Urdaniz, JI; Manterola Burgaleta, A; Martínez Aguillo, M; Salgado Pascual, E; Vera García, R; Villafranca Iturre, E, 2006) |
| "Treatment of locally advanced pancreatic cancer with high-dose radiotherapy has not been curative, and can be difficult to tolerate." | 1.33 | Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. ( Abbruzzese, JL; Crane, CH; Delclos, ME; Evans, DB; Ho, L; Tamm, EP; Wolff, RA; Wong, AA; Xiong, HQ, 2005) |
| "The prognosis of locally advanced cervix cancers is poor with metastatic and local recurrence risks." | 1.31 | [Chemoradiotherapy in locally advanced cancers of the uterine neck. Retrospective study of 92 patients treated at the Institute Curie between 1986 and 1998]]. ( Beuzeboc, P; Chauveinc, L; Clough, KB; Cosset, JM; de la Rochefordière, A; Guyonnet, M; Mouret-Fourme, E; Nguyen, D, 2002) |
| "In the patients with squamous cell carcinoma, 100 mg/m2 of cisplatin was infused intravenously, followed immediately by five consecutive daily administrations of 5-fluorouracil, 1,000 mg/m2/day, each infused intravenously over 24 hr." | 1.31 | Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors. ( Kim, GE; Kim, SN; Kim, SW; Park, TK; Suh, CO, 2000) |
| " The reduction of gastrointestinal (GI) toxicity, induced in the host by 5-FU, was modulated by potassium oxonate (Oxo), an inhibitor of orotate phosphoribosyltransferase that catalyzes the phosphorylation of 5-FU, a process believed to be responsible for the toxic effects of 5-FU." | 1.29 | Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. ( Fukushima, M; Kato, T; Ohshimo, H; Shimamato, Y; Shirasaka, T; Yamaguchi, M; Yonekura, K, 1996) |
| "Selective protection of the normal host tissues from the toxic effects of anticancer agents would allow the use of higher, probably more effective, doses of the drugs." | 1.29 | Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high-dose uridine. ( Bagrij, T; Kerpel-Fronius, S; Kiss, E; Kralovanszky, J; Peters, GJ; Prajda, N, 1993) |
| "48 patients with colorectal cancer metastatic to the liver were implanted with a subcutaneous access system allowing hepatic intra-arterial perfusion." | 1.28 | Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. ( Ducreux, M; Elias, D; Lasser, PH; Lumbroso, J; Pignon, JP; Rougier, P; Ruffie, P; Tigaud, JM, 1991) |
| "To determine the maximum tolerated dose of 5-fluorouracil administered as a 120-hour continuous intravenous infusion to pediatric patients, we performed a phase I study using a starting dosage of 900 mg/m2/day." | 1.28 | Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: a Pediatric Oncology Group study. ( Bell, B; Brecher, ML; Cushing, B; Green, DM; Krischer, JP; Whitehead, VM, 1990) |
| "5-Fluorouracil (FUra) is a clinically useful antineoplastic agent." | 1.27 | Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid. ( Casper, ES; Martin, DS; Vale, K; Williams, LJ; Young, CW, 1983) |
| "Twenty-three patients with advanced colorectal cancer were treated with folinic acid (200 mg/m2/day 1-5 IV bolus injection) and 5-fluorouracil (400 mg/m2/day 1-5 IV in 15 minutes) every 28 days." | 1.27 | High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer. ( Bartolucci, R; Brugia, M; Buzzi, F; Di Costanzo, F; Padalino, D, 1988) |
| " However, severe myelosuppression occurred at the 800 mg/m2 dosage which led to marked leukopenia in 5 of the 6 patient courses and thrombocytopenia in 1." | 1.27 | Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule. ( Ahmann, FR; Garewal, H, 1986) |
| " Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures." | 1.27 | Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer. ( Camacho, FJ; Engstrom, PF; Green, MD; Greenwald, ES; Kaplan, BH; Muggia, FM; Wernz, JC, 1987) |
| "Other nonneoplastic gastrointestinal disorders showed an 18% abnormal CSAp titer frequency, of which more than half bordered the upper limit of normalcy." | 1.26 | Colon-specific antigen-p (CSAp). I. Initial clinical evaluation as a marker for colorectal cancer. ( Goldenberg, DM; Nelson, MO; Pant, KD; Shochat, D, 1982) |
| " Gastrointestinal and hematologic toxic effects were mild and infrequent." | 1.26 | High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule. ( Campbell, TN; House, BA; Howell, SB; Pfeifle, C, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (21.37) | 18.7374 |
| 1990's | 15 (11.45) | 18.2507 |
| 2000's | 48 (36.64) | 29.6817 |
| 2010's | 37 (28.24) | 24.3611 |
| 2020's | 3 (2.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, KJ | 1 |
| Huang, YL | 1 |
| Kuo, LM | 1 |
| Chen, YT | 1 |
| Hung, CF | 1 |
| Hsieh, PW | 1 |
| Yeung, CY | 1 |
| Chiang Chiau, JS | 1 |
| Cheng, ML | 1 |
| Chan, WT | 1 |
| Chang, SW | 1 |
| Chang, YH | 1 |
| Jiang, CB | 1 |
| Lee, HC | 1 |
| McQuade, RM | 2 |
| Al Thaalibi, M | 1 |
| Nurgali, K | 2 |
| Forsgård, RA | 2 |
| Marrachelli, VG | 1 |
| Korpela, K | 1 |
| Frias, R | 2 |
| Collado, MC | 1 |
| Korpela, R | 2 |
| Monleon, D | 1 |
| Spillmann, T | 2 |
| Österlund, P | 3 |
| Bachet, JB | 1 |
| Lucidarme, O | 1 |
| Levache, CB | 1 |
| Barbier, E | 1 |
| Raoul, JL | 1 |
| Lecomte, T | 2 |
| Desauw, C | 1 |
| Brocard, F | 1 |
| Pernot, S | 1 |
| Breysacher, G | 1 |
| Lagasse, JP | 1 |
| Di Fiore, F | 1 |
| Etienne, PL | 1 |
| Dupuis, OJM | 1 |
| Aleba, A | 1 |
| Lepage, C | 1 |
| Taieb, J | 2 |
| Lunenburg, CATC | 1 |
| Henricks, LM | 2 |
| Dreussi, E | 1 |
| Peters, FP | 1 |
| Fiocco, M | 1 |
| Meulendijks, D | 2 |
| Toffoli, G | 1 |
| Guchelaar, HJ | 1 |
| Swen, JJ | 1 |
| Cecchin, E | 1 |
| Schellens, JHM | 1 |
| Gelderblom, H | 1 |
| Chen, LT | 2 |
| Siveke, JT | 1 |
| Wang-Gillam, A | 2 |
| Li, CP | 1 |
| Bodoky, G | 1 |
| Dean, AP | 1 |
| Shan, YS | 1 |
| Jameson, GS | 1 |
| Macarulla, T | 1 |
| Lee, KH | 1 |
| Cunningham, D | 3 |
| Blanc, JF | 1 |
| Chiu, CF | 1 |
| Schwartsmann, G | 1 |
| Braiteh, FS | 1 |
| Mamlouk, K | 1 |
| Belanger, B | 1 |
| de Jong, FA | 1 |
| Hubner, RA | 1 |
| Korver, SK | 1 |
| Gibson, RJ | 1 |
| Bowen, JM | 2 |
| Coller, JK | 2 |
| Nichols, RC | 1 |
| George, TJ | 1 |
| Zaiden, RA | 1 |
| Awad, ZT | 1 |
| Asbun, HJ | 1 |
| Huh, S | 1 |
| Ho, MW | 1 |
| Mendenhall, NP | 1 |
| Morris, CG | 1 |
| Hoppe, BS | 1 |
| Taghizadeh Davoudi, E | 1 |
| Ibrahim Noordin, M | 1 |
| Kadivar, A | 1 |
| Kamalidehghan, B | 1 |
| Farjam, AS | 1 |
| Akbari Javar, H | 1 |
| Call, JA | 1 |
| Prendergast, BM | 1 |
| Jensen, LG | 1 |
| Ord, CB | 1 |
| Goodman, KA | 1 |
| Jacob, R | 1 |
| Mell, LK | 1 |
| Thomas, CR | 1 |
| Jabbour, SK | 1 |
| Miller, RC | 1 |
| Cardani, D | 1 |
| Sardi, C | 1 |
| La Ferla, B | 1 |
| D'Orazio, G | 1 |
| Sommariva, M | 1 |
| Marcucci, F | 1 |
| Olivero, D | 1 |
| Tagliabue, E | 1 |
| Koepsell, H | 1 |
| Nicotra, F | 1 |
| Balsari, A | 1 |
| Rumio, C | 1 |
| Toh, JW | 1 |
| Morris, D | 1 |
| Chen, Z | 1 |
| Chen, C | 1 |
| Lee, CS | 1 |
| Ryan, EJ | 1 |
| Doherty, GA | 1 |
| White, IA | 1 |
| Logan, RM | 1 |
| Tuke, J | 1 |
| Richards, AM | 1 |
| Mead, KR | 1 |
| Karapetis, CS | 1 |
| Muto, O | 1 |
| Sawada, T | 1 |
| Kotanagi, K | 1 |
| Sato, K | 1 |
| Kichiraku, T | 1 |
| Iwasaki, W | 1 |
| Kikkawa, M | 1 |
| Ouchi, S | 1 |
| Kotanagi, H | 1 |
| Bano, N | 1 |
| Najam, R | 1 |
| Qazi, F | 1 |
| Mateen, A | 1 |
| Kajiwara, T | 1 |
| Miura, K | 1 |
| Ohnuma, S | 1 |
| Shimada, M | 1 |
| Komura, T | 1 |
| Toshima, M | 1 |
| Kohyama, A | 1 |
| Kudoh, K | 1 |
| Haneda, S | 1 |
| Musha, H | 1 |
| Naitoh, T | 1 |
| Shirasaka, T | 2 |
| Unno, M | 1 |
| Yeung, R | 2 |
| McConnell, Y | 1 |
| Warkentin, H | 1 |
| Graham, D | 1 |
| Warkentin, B | 1 |
| Joseph, K | 1 |
| Doll, CM | 1 |
| Badiyan, SN | 1 |
| Olsen, JR | 1 |
| Lee, AY | 1 |
| Yano, M | 1 |
| Menias, CO | 1 |
| Khwaja, S | 1 |
| Strasberg, SM | 1 |
| Hawkins, WG | 1 |
| Linehan, DC | 1 |
| Myerson, RJ | 1 |
| Parikh, PJ | 1 |
| Sonke, GS | 1 |
| Deenen, MJ | 1 |
| Froehlich, TK | 1 |
| Amstutz, U | 1 |
| Largiadèr, CR | 1 |
| Jennings, BA | 1 |
| Marinaki, AM | 1 |
| Sanderson, JD | 1 |
| Kleibl, Z | 2 |
| Kleiblova, P | 2 |
| Schwab, M | 1 |
| Zanger, UM | 1 |
| Palles, C | 1 |
| Tomlinson, I | 1 |
| Gross, E | 1 |
| van Kuilenburg, AB | 1 |
| Punt, CJ | 1 |
| Koopman, M | 1 |
| Beijnen, JH | 1 |
| Cats, A | 1 |
| Schellens, JH | 1 |
| Khemissa, F | 1 |
| Mineur, L | 2 |
| Amsellem, C | 1 |
| Assenat, E | 1 |
| Ramdani, M | 1 |
| Bachmann, P | 1 |
| Janiszewski, C | 1 |
| Cristiani, I | 1 |
| Collin, F | 1 |
| Courraud, J | 1 |
| de Forges, H | 1 |
| Dechelotte, P | 1 |
| Senesse, P | 1 |
| Stojanovska, V | 1 |
| Donald, E | 1 |
| Abalo, R | 1 |
| Bornstein, JC | 1 |
| Chllamma, MK | 1 |
| Cook, N | 1 |
| Dhani, NC | 1 |
| Giby, K | 1 |
| Dodd, A | 1 |
| Wang, L | 1 |
| Hedley, DW | 1 |
| Moore, MJ | 1 |
| Knox, JJ | 1 |
| Martin-Romano, P | 1 |
| Sola, JJ | 1 |
| Diaz-Gonzalez, JA | 1 |
| Chopitea, A | 1 |
| Iragorri, Y | 1 |
| Martínez-Regueira, F | 1 |
| Ponz-Sarvise, M | 1 |
| Arbea, L | 1 |
| Subtil, JC | 1 |
| Cano, D | 1 |
| Ceniceros, L | 1 |
| Legaspi, J | 1 |
| Hernandez, JL | 1 |
| Rodríguez, J | 1 |
| Holma, R | 1 |
| Lindén, J | 1 |
| Kuchay, RA | 1 |
| Becerra, CR | 1 |
| Verma, UN | 1 |
| Tran, HT | 1 |
| Tavana, D | 1 |
| Williams, NS | 1 |
| Frenkel, EP | 1 |
| Loibl, S | 1 |
| von Minckwitz, G | 1 |
| Harbeck, N | 1 |
| Janni, W | 1 |
| Elling, D | 1 |
| Kaufmann, M | 1 |
| Eggemann, H | 1 |
| Nekljudova, V | 1 |
| Sommer, H | 1 |
| Kiechle, M | 1 |
| Kümmel, S | 1 |
| Gu, Y | 1 |
| Shu, Y | 1 |
| Xu, Q | 1 |
| Saegusa, Y | 2 |
| Ichikawa, T | 2 |
| Iwai, T | 2 |
| Goso, Y | 2 |
| Okayasu, I | 1 |
| Ikezawa, T | 2 |
| Shikama, N | 2 |
| Saigenji, K | 2 |
| Ishihara, K | 2 |
| Frye, DK | 1 |
| Cao, W | 1 |
| Yang, W | 1 |
| Lou, G | 1 |
| Jiang, J | 1 |
| Geng, M | 1 |
| Xi, W | 1 |
| Li, H | 1 |
| Ma, T | 1 |
| Jin, Y | 1 |
| Zhao, JG | 1 |
| Qiu, F | 1 |
| Xiong, JP | 1 |
| Zhang, L | 1 |
| Xiang, XJ | 1 |
| Yu, F | 1 |
| Yan, J | 1 |
| Zhan, ZY | 1 |
| Feng, M | 1 |
| Ticha, I | 1 |
| Fidlerova, J | 1 |
| Novotny, J | 1 |
| Pohlreich, P | 1 |
| Salah-Eldin, MA | 1 |
| Ebrahim, MA | 1 |
| AL-Ashry, MS | 1 |
| Degirmenci, M | 1 |
| Karaca, B | 1 |
| Gorumlu, G | 1 |
| Durusoy, R | 1 |
| Demir Piskin, G | 1 |
| Bozkurt, MT | 1 |
| Cirak, Y | 1 |
| Tunali, D | 1 |
| Karabulut, B | 1 |
| Sanli, UA | 1 |
| Uslu, R | 1 |
| Ozdemir, NY | 1 |
| Abali, H | 1 |
| Oksüzoğlu, B | 1 |
| Budakoglu, B | 1 |
| Uncu, D | 1 |
| Güler, T | 1 |
| Odabaşi, H | 1 |
| Zengin, N | 1 |
| Farhat, FS | 1 |
| Kattan, J | 1 |
| Chahine, GY | 1 |
| Younes, FC | 1 |
| Nasr, FL | 1 |
| Mroue, RM | 1 |
| Ghosn, MG | 1 |
| Kim, BG | 2 |
| Oh, SY | 1 |
| Kwon, HC | 1 |
| Lee, S | 1 |
| Lee, DM | 1 |
| Kim, SG | 1 |
| Kim, DK | 1 |
| Jang, JS | 1 |
| Kim, MC | 1 |
| Kim, SH | 1 |
| Kim, HJ | 1 |
| Malik, I | 1 |
| Hussein, F | 1 |
| Bush, D | 1 |
| Alqaisi, M | 1 |
| Bernal, P | 1 |
| Byrd, J | 1 |
| Garberoglio, C | 1 |
| Chen, RC | 2 |
| Mamon, HJ | 2 |
| Chen, YH | 1 |
| Gelman, RS | 1 |
| Suh, WW | 1 |
| Talcott, JA | 1 |
| Clark, JW | 2 |
| Hong, TS | 2 |
| Cartwright, T | 1 |
| McCollum, D | 1 |
| Boehm, KA | 1 |
| Mikhail, SE | 1 |
| Sun, JF | 1 |
| Marshall, JL | 1 |
| Barhoumi, M | 1 |
| Mornex, F | 1 |
| Bonnetain, F | 2 |
| Rougier, P | 3 |
| Mariette, C | 1 |
| Bouché, O | 1 |
| Bosset, JF | 1 |
| Aparicio, T | 1 |
| Azzedine, A | 1 |
| Hammel, P | 1 |
| Butel, J | 1 |
| Stremsdoerfer, N | 1 |
| Maingon, P | 1 |
| Bedenne, L | 2 |
| Chauffert, B | 1 |
| Hu, CY | 1 |
| Chan, W | 1 |
| Delclos, GP | 1 |
| Du, XL | 1 |
| Goto, T | 1 |
| Matsubara, T | 1 |
| Yoshizawa, Y | 1 |
| Sasaya, S | 1 |
| Nemoto, H | 1 |
| Sanada, Y | 1 |
| Moriyama, K | 1 |
| Kouchi, Y | 1 |
| Brixi-Benmansour, H | 1 |
| Jouve, JL | 1 |
| Mitry, E | 2 |
| Landi, B | 1 |
| Hentic, O | 1 |
| Cadiot, G | 1 |
| Ancukiewicz, M | 1 |
| Killoran, JH | 1 |
| Crowley, EM | 1 |
| Blaszkowsky, LS | 1 |
| Wo, JY | 1 |
| Ryan, DP | 2 |
| Boige, V | 1 |
| Artru, P | 2 |
| Ezenfis, J | 1 |
| Clavero-Fabri, MC | 1 |
| Vaillant, JN | 1 |
| Ducreux, M | 2 |
| Hegewisch-Becker, S | 1 |
| Gruber, Y | 1 |
| Corovic, A | 1 |
| Pichlmeier, U | 1 |
| Atanackovic, D | 1 |
| Nierhaus, A | 1 |
| Hossfeld, DK | 1 |
| Nguyen, D | 1 |
| de la Rochefordière, A | 1 |
| Chauveinc, L | 1 |
| Cosset, JM | 1 |
| Clough, KB | 1 |
| Beuzeboc, P | 1 |
| Mouret-Fourme, E | 1 |
| Guyonnet, M | 1 |
| Di Paolo, A | 1 |
| Ibrahim, T | 1 |
| Danesi, R | 1 |
| Maltoni, M | 1 |
| Vannozzi, F | 1 |
| Flamini, E | 1 |
| Zoli, W | 1 |
| Amadori, D | 1 |
| Del Tacca, M | 1 |
| Liu, TW | 1 |
| Wu, CW | 1 |
| Chung, TR | 1 |
| Shiah, HS | 1 |
| Jan, CM | 1 |
| Liu, JM | 1 |
| Whang-Peng, J | 1 |
| Chang, JY | 1 |
| Louvet, C | 2 |
| Carrat, F | 1 |
| Mal, F | 1 |
| Mabro, M | 2 |
| Beerblock, K | 1 |
| Vaillant, JC | 1 |
| Cady, J | 1 |
| André, T | 2 |
| Gamelin, E | 2 |
| de Gramont, A | 2 |
| Lorvidhaya, V | 1 |
| Chitapanarux, I | 1 |
| Sangruchi, S | 1 |
| Lertsanguansinchai, P | 1 |
| Kongthanarat, Y | 1 |
| Tangkaratt, S | 1 |
| Visetsiri, E | 1 |
| Eder, JP | 1 |
| Garcia-Carbonero, R | 1 |
| Supko, JG | 1 |
| Puchalski, TA | 1 |
| Deluca, P | 1 |
| Wozniak, A | 1 |
| Campbell, A | 1 |
| Rothermel, J | 1 |
| LoRusso, P | 1 |
| Jefford, M | 1 |
| Michael, M | 1 |
| Rosenthal, MA | 1 |
| Davis, ID | 1 |
| Green, M | 1 |
| McClure, B | 1 |
| Smith, J | 1 |
| Waite, B | 1 |
| Zalcberg, J | 1 |
| Hasegawa, S | 1 |
| Akaike, M | 1 |
| Yamamoto, Y | 1 |
| Shiraishi, R | 1 |
| Ozawa, Y | 1 |
| Suzuki, H | 1 |
| Miyazaki, T | 1 |
| Kasahara, A | 1 |
| Makino, T | 1 |
| Tamura, I | 1 |
| Tanabe, H | 1 |
| Rino, Y | 1 |
| Saigi, E | 1 |
| Salut, A | 1 |
| Campos, JM | 1 |
| Losa, F | 1 |
| Manzano, H | 1 |
| Batiste-Alentorn, E | 1 |
| Acusa, A | 1 |
| Vélez de Mendizabal, E | 1 |
| Guasch, I | 1 |
| Antón, I | 1 |
| Chau, I | 1 |
| Norman, AR | 1 |
| Tait, D | 1 |
| Ross, PJ | 1 |
| Iveson, T | 1 |
| Hill, M | 1 |
| Hickish, T | 1 |
| Lofts, F | 1 |
| Jodrell, D | 1 |
| Webb, A | 1 |
| Oates, JR | 1 |
| Wong, AA | 1 |
| Delclos, ME | 1 |
| Wolff, RA | 1 |
| Evans, DB | 1 |
| Abbruzzese, JL | 1 |
| Tamm, EP | 1 |
| Xiong, HQ | 1 |
| Ho, L | 1 |
| Crane, CH | 1 |
| Correale, P | 1 |
| Fulfaro, F | 1 |
| Marsili, S | 1 |
| Cicero, G | 1 |
| Bajardi, E | 1 |
| Intrivici, C | 1 |
| Vuolo, G | 1 |
| Carli, AF | 1 |
| Caraglia, M | 1 |
| Del Prete, S | 1 |
| Greco, E | 1 |
| Gebbia, N | 1 |
| Francini, G | 1 |
| Mackay, HJ | 1 |
| Billingsley, K | 1 |
| Gallinger, S | 1 |
| Berry, S | 1 |
| Smith, A | 1 |
| Pond, GR | 1 |
| Croitoru, M | 1 |
| Swanson, PE | 1 |
| Krishnamurthi, S | 1 |
| Siu, LL | 1 |
| Yagüe, XH | 1 |
| Soy, E | 1 |
| Merino, BQ | 1 |
| Puig, J | 1 |
| Fabregat, MB | 1 |
| Colomer, R | 1 |
| Jones, JA | 1 |
| Avritscher, EB | 1 |
| Cooksley, CD | 1 |
| Michelet, M | 1 |
| Bekele, BN | 1 |
| Elting, LS | 1 |
| Arraras Urdaniz, JI | 1 |
| Arias de la Vega, F | 1 |
| Vera García, R | 1 |
| Manterola Burgaleta, A | 1 |
| Martínez Aguillo, M | 1 |
| Villafranca Iturre, E | 1 |
| Salgado Pascual, E | 1 |
| Hofheinz, RD | 1 |
| Kubicka, S | 1 |
| Wollert, J | 1 |
| Arnold, D | 1 |
| Hochhaus, A | 1 |
| Choi, CH | 1 |
| Lee, JW | 1 |
| Kim, TJ | 1 |
| Kim, WY | 1 |
| Nam, HR | 1 |
| Huh, SJ | 1 |
| Lee, JH | 1 |
| Bae, DS | 1 |
| Capitain, O | 1 |
| Boisdron-Celle, M | 1 |
| Poirier, AL | 1 |
| Abadie-Lacourtoisie, S | 1 |
| Morel, A | 1 |
| Zhang, HG | 1 |
| Cai, RG | 1 |
| Chen, SS | 1 |
| Wu, F | 1 |
| Chu, DT | 1 |
| Chang, PM | 1 |
| Chen, PM | 1 |
| Chu, PY | 1 |
| Wang, LW | 1 |
| Tai, SK | 1 |
| Tsai, TL | 1 |
| Huang, JL | 1 |
| Wang, YF | 1 |
| Chang, SY | 1 |
| Yang, MH | 1 |
| Valentini, V | 1 |
| De Paoli, A | 1 |
| Gambacorta, MA | 1 |
| Mantini, G | 1 |
| Ratto, C | 1 |
| Vecchio, FM | 1 |
| Barbaro, B | 1 |
| Innocente, R | 1 |
| Rossi, C | 1 |
| Boz, G | 1 |
| Barba, MC | 1 |
| Frattegiani, A | 1 |
| Lupattelli, M | 1 |
| Doglietto, GB | 1 |
| Nakano, M | 1 |
| Puglisi, F | 1 |
| Cardellino, GG | 1 |
| Crivellari, D | 1 |
| Di Loreto, C | 1 |
| Magri, MD | 1 |
| Minisini, AM | 1 |
| Mansutti, M | 1 |
| Andreetta, C | 1 |
| Russo, S | 1 |
| Lombardi, D | 1 |
| Perin, T | 1 |
| Damante, G | 1 |
| Veronesi, A | 1 |
| Haller, DG | 1 |
| Cassidy, J | 1 |
| Clarke, SJ | 1 |
| Van Cutsem, E | 2 |
| Hoff, PM | 1 |
| Rothenberg, ML | 2 |
| Saltz, LB | 1 |
| Schmoll, HJ | 1 |
| Allegra, C | 1 |
| Bertino, JR | 2 |
| Douillard, JY | 1 |
| Gustavsson, BG | 1 |
| Milano, G | 1 |
| O'Connell, M | 1 |
| Rustum, Y | 1 |
| Tabernero, J | 1 |
| Gilberg, F | 1 |
| Sirzén, F | 1 |
| Twelves, C | 3 |
| Pant, KD | 1 |
| Shochat, D | 1 |
| Nelson, MO | 1 |
| Goldenberg, DM | 1 |
| Higgins, GA | 2 |
| Donaldson, RC | 1 |
| Rogers, LS | 1 |
| Juler, GL | 1 |
| Keehn, RJ | 2 |
| Barone, RM | 1 |
| Byfield, JE | 2 |
| Goldfarb, PB | 1 |
| Frankel, S | 1 |
| Ginn, C | 1 |
| Greer, S | 1 |
| Bukowski, RM | 2 |
| Balcerzak, SP | 1 |
| O'Bryan, RM | 1 |
| Bonnet, JD | 1 |
| Chen, TT | 1 |
| Cunningham, J | 1 |
| Budd, GT | 1 |
| Weick, JK | 1 |
| Purvis, J | 1 |
| Pitman, SW | 1 |
| Kowal, CD | 1 |
| Amadeo, JH | 1 |
| McElhinney, J | 1 |
| McCaughan, JJ | 1 |
| Engstrom, PF | 2 |
| MacIntyre, JM | 1 |
| Mittelman, A | 1 |
| Klaassen, DJ | 1 |
| Sharp, TR | 1 |
| Frankel, SS | 1 |
| Tang, SG | 1 |
| Callipari, FB | 1 |
| Cummings, BJ | 1 |
| Rider, WD | 1 |
| Harwood, AR | 1 |
| Keane, TJ | 1 |
| Thomas, GM | 1 |
| Erlichman, C | 1 |
| Fine, S | 1 |
| Lawson, DH | 1 |
| Nixon, DW | 1 |
| Kutner, MH | 1 |
| Heymsfield, SB | 1 |
| Rudman, D | 1 |
| Moffitt, S | 1 |
| Ansley, J | 1 |
| Chawla, R | 1 |
| Casper, ES | 1 |
| Vale, K | 1 |
| Williams, LJ | 1 |
| Martin, DS | 1 |
| Young, CW | 1 |
| Campbell, TN | 1 |
| Howell, SB | 1 |
| Pfeifle, C | 1 |
| House, BA | 1 |
| Jäger, E | 1 |
| Bernhard, H | 1 |
| Klein, O | 1 |
| Wächter, B | 1 |
| Theiss, F | 1 |
| Dippold, W | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Knuth, A | 1 |
| Köhne, CH | 1 |
| Hiddemann, W | 1 |
| Schüller, J | 1 |
| Weiss, J | 1 |
| Lohrmann, HP | 1 |
| Schmitz-Hübner, U | 1 |
| Bodenstein, H | 1 |
| Schöber, C | 1 |
| Wilke, H | 1 |
| Grem, J | 1 |
| Frasci, G | 1 |
| Leone, F | 1 |
| Monaco, M | 1 |
| Cremone, L | 1 |
| Sapio, U | 1 |
| Faiella, F | 1 |
| Espinosa, A | 1 |
| Persico, G | 1 |
| Landry, JC | 1 |
| Koretz, MJ | 1 |
| Wood, WC | 1 |
| Bahri, S | 1 |
| Smith, RG | 1 |
| Costa, M | 1 |
| Daneker, GW | 1 |
| York, MR | 1 |
| Sarma, PR | 1 |
| Lynn, M | 1 |
| Cvitkovic, FB | 1 |
| Haie-Meder, C | 1 |
| Papadimitrakopoulou, V | 1 |
| Armand, JP | 1 |
| Cioloca, C | 1 |
| Maugis, N | 1 |
| Constans, JP | 1 |
| Kralovanszky, J | 1 |
| Prajda, N | 1 |
| Kerpel-Fronius, S | 1 |
| Bagrij, T | 1 |
| Kiss, E | 1 |
| Peters, GJ | 1 |
| Shimamato, Y | 1 |
| Ohshimo, H | 1 |
| Yamaguchi, M | 1 |
| Kato, T | 1 |
| Yonekura, K | 1 |
| Fukushima, M | 1 |
| Hietanen, P | 1 |
| Teerenhovi, L | 1 |
| Joensuu, H | 2 |
| Kimura, Y | 1 |
| Okuda, H | 1 |
| Soori, GS | 1 |
| Oldham, RK | 1 |
| Dobbs, TW | 1 |
| Bury, MJ | 1 |
| Church, CK | 1 |
| DePriest, C | 1 |
| Pronk, LC | 1 |
| Vasey, P | 1 |
| Sparreboom, A | 1 |
| Reigner, B | 1 |
| Planting, AS | 1 |
| Gordon, RJ | 1 |
| Osterwalder, B | 1 |
| Verweij, J | 1 |
| Riva, C | 1 |
| Lavieille, JP | 1 |
| Schmerber, S | 1 |
| Cuisnie, O | 1 |
| Reyt, E | 1 |
| Park, TK | 1 |
| Kim, SN | 1 |
| Kim, SW | 1 |
| Kim, GE | 1 |
| Suh, CO | 1 |
| Sobrero, A | 1 |
| Zaniboni, A | 2 |
| Frassineti, GL | 1 |
| Aschele, C | 1 |
| Guglielmi, A | 1 |
| Giuliani, R | 1 |
| Ravaioli, A | 1 |
| Lanfranco, C | 1 |
| Caroti, C | 1 |
| Arnoldi, E | 1 |
| Barni, S | 1 |
| Gallo, L | 1 |
| Pessi, MA | 1 |
| Turci, D | 1 |
| Cortesi, E | 1 |
| Grossi, F | 1 |
| Frontini, L | 1 |
| Piazza, E | 1 |
| Bruzzi, P | 1 |
| Labianca, R | 1 |
| Belpomme, D | 1 |
| Gauthier, S | 1 |
| Pujade-Lauraine, E | 1 |
| Facchini, T | 1 |
| Goudier, MJ | 1 |
| Krakowski, I | 1 |
| Netter-Pinon, G | 1 |
| Frenay, M | 1 |
| Gousset, C | 1 |
| Marié, FN | 1 |
| Benmiloud, M | 1 |
| Sturtz, F | 1 |
| Maindrault-Goebel, F | 1 |
| Carola, E | 1 |
| Gilles, V | 1 |
| Lotz, JP | 1 |
| Tournigand, C | 1 |
| Molitor, JL | 1 |
| Izrael, V | 1 |
| Krulik, M | 1 |
| Elomaa, I | 1 |
| Virkkunen, P | 1 |
| Meropol, NJ | 1 |
| Poplin, EA | 1 |
| Wadler, S | 1 |
| Stockeld, D | 1 |
| Tennvall, J | 1 |
| Wagenius, G | 1 |
| Albertsson, M | 1 |
| Backman, L | 1 |
| Brodin, O | 1 |
| Cwikiel, M | 1 |
| Granström, L | 1 |
| Gustafsson, G | 1 |
| Gustavsson, S | 1 |
| Hambraeus, G | 1 |
| Lewensohn, R | 1 |
| Sjöstedt, S | 1 |
| Strander, H | 1 |
| Aberg, B | 1 |
| Fagerberg, J | 1 |
| Honecker, F | 1 |
| Kollmannsberger, C | 1 |
| Quietzsch, D | 1 |
| Haag, C | 1 |
| Schroeder, M | 1 |
| Spott, C | 1 |
| Hartmann, JT | 1 |
| Baronius, W | 1 |
| Hempel, V | 1 |
| Kanz, L | 1 |
| Bokemeyer, C | 1 |
| O'Shaughnessy, J | 1 |
| Miles, D | 1 |
| Vukelja, S | 1 |
| Moiseyenko, V | 1 |
| Ayoub, JP | 1 |
| Cervantes, G | 1 |
| Fumoleau, P | 1 |
| Jones, S | 1 |
| Lui, WY | 1 |
| Mauriac, L | 1 |
| Van Hazel, G | 1 |
| Verma, S | 1 |
| Leonard, R | 1 |
| Valdivieso, M | 1 |
| Bodey, GP | 1 |
| Gottlieb, JA | 1 |
| Freireich, EJ | 1 |
| Sandovsky-Losica, H | 1 |
| Barr-Nea, L | 1 |
| Segal, E | 1 |
| Pignon, JP | 1 |
| Elias, D | 1 |
| Tigaud, JM | 1 |
| Lumbroso, J | 1 |
| Ruffie, P | 1 |
| Lasser, PH | 1 |
| Ardalan, B | 1 |
| Sridhar, KS | 1 |
| Benedetto, P | 1 |
| Richman, S | 1 |
| Waldman, S | 1 |
| Morrell, L | 1 |
| Feun, L | 1 |
| Savaraj, N | 1 |
| Fodor, M | 1 |
| Livingstone, A | 1 |
| Saphner, T | 1 |
| Tormey, DC | 1 |
| Albertini, M | 1 |
| Weiss, GR | 1 |
| Green, S | 1 |
| Hannigan, EV | 1 |
| Boutselis, JG | 1 |
| Surwit, EA | 1 |
| Wallace, DL | 1 |
| Alberts, DS | 1 |
| Green, DM | 1 |
| Krischer, JP | 1 |
| Bell, B | 1 |
| Brecher, ML | 1 |
| Cushing, B | 1 |
| Whitehead, VM | 1 |
| Di Costanzo, F | 1 |
| Bartolucci, R | 1 |
| Padalino, D | 1 |
| Brugia, M | 1 |
| Buzzi, F | 1 |
| Marini, G | 1 |
| Simoncini, E | 1 |
| Gorni, F | 1 |
| Marpicati, P | 1 |
| Zambruni, A | 1 |
| Schnitzler, G | 1 |
| Queisser, W | 1 |
| Heim, ME | 1 |
| König, H | 1 |
| Katz, R | 1 |
| Fritze, D | 1 |
| Herrmann, R | 1 |
| Arnold, H | 1 |
| Henss, H | 1 |
| Trux, FA | 1 |
| Dy, C | 1 |
| Gil, A | 1 |
| Algarra, SM | 1 |
| Aparicio, LA | 1 |
| Calvo, F | 1 |
| Herranz, P | 1 |
| Garewal, H | 1 |
| Ahmann, FR | 1 |
| Muggia, FM | 1 |
| Camacho, FJ | 1 |
| Kaplan, BH | 1 |
| Green, MD | 1 |
| Greenwald, ES | 1 |
| Wernz, JC | 1 |
| Loehrer, PJ | 1 |
| Einhorn, LH | 1 |
| Williams, SD | 1 |
| Hui, SL | 1 |
| Estes, NC | 1 |
| Pennington, K | 1 |
| Huys, J | 1 |
| Van Vaerenbergh, PM | 1 |
| Ahmann, DL | 2 |
| Bisel, HF | 2 |
| Hahn, RG | 2 |
| Moertel, CG | 1 |
| Schutt, AJ | 1 |
| Dines, DE | 1 |
| Jacobs, EM | 1 |
| Reeves, WJ | 1 |
| Wood, DA | 1 |
| Pugh, R | 1 |
| Braunwald, J | 1 |
| Bateman, JR | 1 |
| Piro, AJ | 1 |
| Wilson, RE | 1 |
| Nevinny, HB | 1 |
| Kovalev, MM | 1 |
| Tanasienko, ID | 1 |
| Govdenko, PF | 1 |
| Geleskul, VF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis[NCT01674309] | Phase 2 | 65 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy[NCT01494506] | Phase 3 | 417 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| The Effectiveness of Topical Oral Vitamin D Gel in Prevention of Radiation-induced Oral Mucositis[NCT04308161] | Phase 2 | 45 participants (Anticipated) | Interventional | 2019-11-02 | Recruiting | ||
| The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis[NCT03833570] | Phase 2 | 40 participants (Actual) | Interventional | 2018-01-12 | Completed | ||
| Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors[NCT00416767] | Phase 2 | 20 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer[NCT04409860] | 120 participants (Anticipated) | Interventional | 2020-05-26 | Recruiting | |||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703] | Phase 2 | 38 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy of Pharmacokinetically-guided and BSA Fixed Dosing Strategy of Docetaxel and Paclitaxel in Chinese Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, and Breast Cancer Patie[NCT01891123] | 300 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
| Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study[NCT00256841] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2005-09-30 | Withdrawn (stopped due to Lack of funding) | ||
| A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine Followed by Capecitabine Alone as 1st Therapy on Locally Advanced and Metastatic Breast Cancer Patients.[NCT01126138] | Phase 3 | 200 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer[NCT01642771] | Phase 3 | 636 participants (Anticipated) | Interventional | 2012-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS. (NCT01494506)
Timeframe: Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.
| Intervention | percentage with confirmed response (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 3.31 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 0.67 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 7.69 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 0.84 |
"Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 4.9 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 4.2 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 6.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 4.2 |
"Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:~(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.~With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.~Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period." (NCT01494506)
Timeframe: Randomization to treatment discontinuation.The maximum time in follow up was 25 months
| Intervention | percentage of participants with CBR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 14 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 13 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 14 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 |
Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of participants with TMR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 23.6 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 28.9 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 8.6 |
"Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 2.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.6 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 3.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.5 |
Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death. (NCT01494506)
Timeframe: Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 1.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2.3 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.4 |
This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of patients in category (Number) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status: Improved | Global Health Status: Stable | Global Health Status: Worsened | Physical Functioning: Improved | Physical Functioning: Stable | Physical Functioning: Worsened | Role Functioning: Improved | Role Functioning: Stable | Role Functioning: Worsened | Emotional Functioning:Improved | Emotional Functioning:Stable | Emotional Functioning:Worsened | Cognitive Functioning:Improved | Cognitive Functioning:Stable | Cognitive Functioning:Worsened | Social Functioning:Improved | Social Functioning:Stable | Social Functioning:Worsened | Fatigue:Improved | Fatigue:Stable | Fatigue:Worsened | Nausea and Vomiting:Improved | Nausea and Vomiting:Stable | Nausea and Vomiting:Worsened | Pain:Improved | Pain:Stable | Pain:Worsened | Dyspnoea:Improved | Dyspnoea:Stable | Dyspnoea:Worsoned | Insomnia:Improved | Insomnia:Stable | Insomnia:Worsened | Appetite Loss:Improved | Appetite Loss:Stable | Appetite Loss:Worsened | Constipation:Improved | Constipation:Stable | Constipation:Worsened | Diarrhoea:Improved | Diarrhoea: Stable | Diarrhoea: Worsened | Financial Difficulties: Improved | Financial Difficulties: Stable | Financial Difficulties: Worsened | |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11 | 41 | 48 | 11 | 37 | 52 | 10 | 39 | 52 | 8 | 59 | 33 | 6 | 42 | 52 | 11 | 43 | 46 | 11 | 30 | 59 | 6 | 42 | 52 | 10 | 37 | 53 | 6 | 69 | 24 | 4 | 49 | 47 | 6 | 42 | 52 | 4 | 63 | 34 | 4 | 58 | 39 | 1 | 67 | 31 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 | 44 | 44 | 11 | 40 | 49 | 11 | 37 | 53 | 9 | 58 | 33 | 7 | 44 | 49 | 11 | 47 | 42 | 12 | 33 | 54 | 4 | 46 | 51 | 11 | 40 | 49 | 5 | 68 | 25 | 5 | 49 | 46 | 5 | 46 | 49 | 4 | 67 | 30 | 4 | 58 | 39 | 0 | 74 | 26 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 17 | 38 | 45 | 10 | 41 | 49 | 15 | 32 | 52 | 20 | 46 | 34 | 11 | 48 | 41 | 13 | 34 | 54 | 14 | 20 | 66 | 13 | 32 | 55 | 27 | 34 | 39 | 7 | 51 | 42 | 18 | 34 | 48 | 11 | 45 | 44 | 13 | 56 | 31 | 6 | 39 | 55 | 8 | 51 | 41 |
| MM-398 Arm A (Mono Therapy Comparison) | 10 | 31 | 57 | 10 | 29 | 61 | 6 | 29 | 66 | 10 | 32 | 56 | 12 | 32 | 54 | 11 | 26 | 62 | 13 | 18 | 69 | 5 | 37 | 58 | 20 | 30 | 50 | 10 | 47 | 44 | 9 | 43 | 48 | 9 | 38 | 53 | 13 | 47 | 39 | 4 | 35 | 59 | 6 | 51 | 42 |
Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods. (NCT01494506)
Timeframe: 6 weeks after first study drug administration
| Intervention | Total irinotecan = ug/L; SN38= ug/L (Geometric Mean) | |||
|---|---|---|---|---|
| Total Irinotecan-Cavg | Total Irinotecan-Cmax | Total SN38-Cavg | Total SN38-Cmax | |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2120.00 | 28460.00 | 0.68 | 2.58 |
| MM-398 Arm A (Mono Therapy Comparison) | 2550.00 | 40550.00 | 0.82 | 3.93 |
11 reviews available for fluorouracil and Cholera Infantum
| Article | Year |
|---|---|
Impact of chemotherapy-induced enteric nervous system toxicity on gastrointestinal mucositis.
Topics: Animals; Antineoplastic Agents; Cisplatin; Enteric Nervous System; Fluorouracil; Gastrointestinal Di | 2020 |
Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Gastrointestinal Diseases; Genetic Markers; Humans; I | 2019 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gas | 2015 |
A review of complementary therapies for chemotherapy induced gastrointestinal mucositis.
Topics: Antimetabolites, Antineoplastic; Complementary Therapies; Fluorouracil; Gastrointestinal Diseases; H | 2017 |
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2008 |
Capecitabine-based combination therapy for breast cancer: implications for nurses.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marr | 2009 |
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant | 2010 |
Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2010 |
Safety of capecitabine: a review.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2010 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
54 trials available for fluorouracil and Cholera Infantum
| Article | Year |
|---|---|
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2018 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pa | 2018 |
A phase III study evaluating oral glutamine and transforming growth factor-beta 2 on chemotherapy-induced toxicity in patients with digestive neoplasm.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Dietary Supplements; Double-Blind Me | 2016 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Pr | 2008 |
A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; C | 2009 |
Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Fema | 2009 |
A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progre | 2009 |
Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C | 2009 |
Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2010 |
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined | 2010 |
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2010 |
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2011 |
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Disease-Free Survival | 2011 |
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2002 |
Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2002 |
A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2002 |
Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2003 |
A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2004 |
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; | 2004 |
[An institution-randomized trial of 5-fluorouracil and l-leucovorin therapy given monthly versus every two months to patients with advanced colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Case-Control Studies; Colo | 2004 |
Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Drug Administration Schedule; | 2004 |
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2005 |
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bio | 2005 |
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Respo | 2006 |
Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2007 |
[10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2007 |
Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092).
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diarrhea; Dru | 2008 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2008 |
Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Clinical Trials as Topic; | 1984 |
Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Therapy, | 1983 |
Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Administration Schedule; Drug Synergism; Dr | 1983 |
Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1984 |
Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1984 |
Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubici | 1984 |
Combination 5-fluorouracil (FU), folinic acid (FA), and alpha-interferon 2B in advanced gastric cancer: results of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1995 |
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1995 |
5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colonic Neoplasms; Confidence | 1994 |
Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1993 |
Chemo-biotherapy with 5-fluorouracil, leucovorin, and alpha interferon in metastatic carcinoma of the colon--a Cancer Biotherapy Research Group [CBRG] phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2000 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; | 2000 |
Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2000 |
Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma.
Topics: Administration, Oral; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2000 |
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 2000 |
A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2001 |
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; B | 1991 |
Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Respo | 1991 |
A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carcinom | 1990 |
Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Doxorubicin; F | 1986 |
A controlled evaluation of 5-fluorouracil utilizing a single injection technique.
Topics: Adenocarcinoma; Alopecia; Evaluation Studies as Topic; Fluorouracil; Gastrointestinal Diseases; Huma | 1974 |
66 other studies available for fluorouracil and Cholera Infantum
| Article | Year |
|---|---|
Protective role of casuarinin from Melastoma malabathricum against a mouse model of 5-fluorouracil-induced intestinal mucositis: Impact on inflammation and gut microbiota dysbiosis.
Topics: Animals; Disease Models, Animal; Dysbiosis; Fluorouracil; Gastrointestinal Diseases; Gastrointestina | 2022 |
Modulations of probiotics on gut microbiota in a 5-fluorouracil-induced mouse model of mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Dietary Supplements; Disease Models, Animal; Fluorouracil; | 2020 |
Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats.
Topics: Animals; Antineoplastic Agents; Camptothecin; Feces; Fluorouracil; Gastrointestinal Diseases; Inflam | 2017 |
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Chemoradioth | 2018 |
Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.
Topics: Adenocarcinoma; Administration, Oral; Aged; Ampulla of Vater; Capecitabine; Chemoradiotherapy; Commo | 2013 |
Preparation and characterization of a gastric floating dosage form of capecitabine.
Topics: Acrylic Resins; Alginates; Breast Neoplasms; Capecitabine; Chemistry, Pharmaceutical; Deoxycytidine; | 2013 |
Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-Institutional Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cape | 2016 |
Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Disease Models, Animal; Doxorub | 2014 |
Near fatal 5-FU gut toxicity post surgery--remarkable effect of high-dose sucralfate.
Topics: Adult; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dihydropyrimid | 2015 |
Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Female; Fluorouracil; Gastrointesti | 2015 |
Modified administration schedule of docetaxel, cisplatin, and fluorouracil for advanced or recurrent gastric cancer with gastrointestinal stenosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; Ga | 2014 |
Gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with different schedules of FOLFOX.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2014 |
Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration.
Topics: Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combinations; Fluorouracil; G | 2015 |
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chem | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2016 |
Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Colon; Enteric Nervous System; Fluorouracil; Gastrointestinal Diseas | 2016 |
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Cam | 2016 |
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2016 |
Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2016 |
Changes in the mucus barrier of the rat during 5-fluorouracil-induced gastrointestinal mucositis.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Fluorouracil; Gastrointestinal Disea | 2008 |
Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Exons; Female; Flu | 2009 |
The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2010 |
Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Diarrhea; Feasibility Studies | 2010 |
Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; | 2012 |
[Diamine oxidase as blood biomarker in rats and humans to GI tract toxicity of fluorouracil anti-cancer drugs].
Topics: Aged; Amine Oxidase (Copper-Containing); Animals; Antimetabolites, Antineoplastic; Biomarkers; Diarr | 2011 |
Dose--volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancer.
Topics: Aged; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Defecation; Deoxycytidine; Diarrhea; F | 2012 |
[Chemoradiotherapy in locally advanced cancers of the uterine neck. Retrospective study of 92 patients treated at the Institute Curie between 1986 and 1998]].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2002 |
Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.
Topics: Aged; Analysis of Variance; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluoroura | 2002 |
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2003 |
Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2005 |
Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Chemothera | 2005 |
Quality of Life assessment through the EORTC questionnaires of locally advanced rectal cancer patients treated with preoperative chemo-radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Image; Emotions | 2006 |
The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Gastr | 2008 |
Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Animals; Anti-Ulcer Agents; Antimetabolites, An | 2008 |
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Cape | 2008 |
Colon-specific antigen-p (CSAp). I. Initial clinical evaluation as a marker for colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Antigens, Neoplasm; Carcinoembryonic Antigen; Colonic Neoplasms; Epitopes; | 1982 |
Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases.
Topics: Adult; Aged; Bone Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Drug Admin | 1982 |
5-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Ga | 1984 |
Phase I and II trial of five-day infused 5-fluorouracil and radiation in advanced cancer of the head and neck.
Topics: Combined Modality Therapy; Drug Administration Schedule; Evaluation Studies as Topic; Fluorouracil; | 1984 |
Combined radical radiation therapy and chemotherapy for primary squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorourac | 1982 |
Enteral versus parenteral nutritional support in cancer patients.
Topics: Animals; Cachexia; Enteral Nutrition; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; | 1981 |
Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Blood Cell Count; Carcinoma; Drug Admin | 1983 |
High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule.
Topics: Adenocarcinoma; Aged; Allopurinol; Brain Diseases; Drug Administration Schedule; Drug Evaluation; Dr | 1982 |
Preoperative irradiation and fluorouracil chemotherapy for locally advanced rectosigmoid carcinoma: phase I-II study.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Mal | 1993 |
Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high-dose uridine.
Topics: Animals; Dose-Response Relationship, Drug; Fluorouracil; Gastrointestinal Diseases; Intestinal Mucos | 1993 |
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Drug Sy | 1996 |
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Drug Sy | 1996 |
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Drug Sy | 1996 |
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Drug Sy | 1996 |
Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer.
Topics: Adult; Aged; Agranulocytosis; Alopecia; Ambulatory Care; Antineoplastic Combined Chemotherapy Protoc | 1999 |
Prevention by carp extract of myelotoxicity and gastrointestinal toxicity induced by 5-fluorouracil without loss of antitumor activity in mice.
Topics: Amino Acids; Animals; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Carps; Chemical and Dru | 1999 |
Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2000 |
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2001 |
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Fluorouracil; Gastroin | 2001 |
Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil).
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Dise | 1976 |
Fatal systemic candidiasis of gastrointestinal origin: an experimental model in mice compromised by anti-cancer treatment.
Topics: Animals; Candida albicans; Candidiasis; Cecum; Chemotherapy, Adjuvant; Disease Models, Animal; Esoph | 1992 |
Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Diseases; Hep | 1991 |
Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: a Pediatric Oncology Group study.
Topics: Adolescent; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Child; Dose-Res | 1990 |
High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Gastr | 1988 |
5-Fluorouracil and high-dose folinic acid as salvage treatment of advanced breast cancer: an update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Drug Evaluat | 1987 |
Combination chemotherapy of cisplatin and 5-FU in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Eval | 1986 |
Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule.
Topics: Adenocarcinoma; Adult; Allopurinol; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Administration | 1986 |
Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Central Nervous System D | 1987 |
Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1985 |
Palliative treatment of metastasized breast cancer with 5-FU in slow intravenous infusion.
Topics: Adult; Breast Neoplasms; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Huma | 1969 |
A phase 2 evaluation of 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea (NSC 95441) in patients with advanced breast cancer.
Topics: Alopecia; Blood Platelets; Breast Neoplasms; Castration; Cyclohexanes; Cyclophosphamide; Drug Evalua | 1974 |
Treatment of cancer with weekly intravenous 5-fluorouracil. Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG).
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Gastrointestinal D | 1971 |
Cyclophosphamide therapy in patients with advancing breast cancer following adrenalectomy and 5-fluorouracil.
Topics: Adrenal Insufficiency; Adrenalectomy; Adult; Aged; Alopecia; Breast Neoplasms; Cortisone; Cyclophosp | 1971 |
[Transumbilical drug infusions in the complex treatment of patients with diseases of the abdominal organs].
Topics: Adult; Aged; Anti-Bacterial Agents; Biliary Tract Diseases; Female; Fluorouracil; Gastrointestinal D | 1971 |